

## NOTICE OF PROPOSED CLASS ACTION SETTLEMENT<sup>1</sup>

**If you purchased Meridian Bioscience, Inc. (“Meridian”) securities between March 24, 2016 and October 23, 2017, inclusive, on a United States stock exchange, and are not otherwise excluded from the Settlement Class (see Question 6 below) you could receive a payment from a class action settlement.**

*A federal court authorized this notice. This is not a solicitation from a lawyer.*

- The proposed Settlement, if approved by the Court, will provide \$2,100,000 to pay claims from investors who bought Meridian securities between March 24, 2016 and October 23, 2017, inclusive (the “Class Period”).
- The Settlement resolves a U.S. lawsuit over whether Meridian made material misrepresentations during the Class Period. Plaintiff and Defendants disagree on whether the investors could have won at trial, and if so, how much money they could receive. Defendants have expressly denied and continue to deny all charges of wrongdoing or liability against them.
- Lead Plaintiff estimates that 18.4 million shares of Meridian common stock are eligible under the Plan of Allocation (described below). If claims are submitted for all of these shares, the estimated distribution per share will be approximately \$0.114 *before* deduction of Court-approved administrative costs, awards to Plaintiff, and any attorneys’ fees and expenses awarded to Plaintiff’s Counsel for their representation of the Settlement Class.
- Lead Counsel has litigated this matter on a contingent basis and advanced all expenses incurred on behalf of the Settlement Class. They will ask the Court for up to \$630,000 in attorneys’ fees (30% of the Settlement Fund) and reimbursement for expenses of up to \$70,000 for their work litigating the case and negotiating the Settlement, and an award to Plaintiff not to exceed \$10,000. If approved, these amounts will be deducted from the \$2,100,000 settlement (totaling \$0.039 per share assuming claims are submitted based on 18.4 million shares).
- After deducting for any attorneys’ fees and expenses and administration costs, the estimated average recovery from the Settlement is \$0.076 per share (assuming claims are submitted on behalf of 18.4 million shares).
- The Court has not yet approved the Settlement. Payments will be made only if the Court approves the Settlement and after any appeals are resolved. Please be patient.
- **Your legal rights are affected whether you act or don’t act. Read this Notice carefully.**

<b><u>YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT</u></b>	
<b>SUBMIT A CLAIM FORM NO LATER THAN FEBRUARY 4, 2020</b>	The only way to get a payment if you have a Recognized Loss.
<b>EXCLUDE YOURSELF NO LATER THAN FEBRUARY 17, 2020</b>	Get no payment. This is the only option that allows you to ever be part of any other lawsuit against the Released Persons about the Released Claims.
<b>OBJECT NO LATER FEBRUARY 17, 2020</b>	Write to the Court about why you do not like the Settlement. You may, but are not required to, appear at the Final Approval Hearing.
<b>GO TO A HEARING</b>	You may ask to speak in Court about the fairness of the Settlement.
<b>DO NOTHING</b>	Get no payment. Give up rights.

<sup>1</sup> This Notice incorporates by reference the definitions in the Amended Stipulation of Settlement dated as of October 7, 2019 (the “Stipulation”), All capitalized terms used, but not defined herein, shall have the same meaning as in the Stipulation. The Stipulation can be obtained at [www.meridiansecuritieslitigation.com](http://www.meridiansecuritieslitigation.com).

For more information, you may contact the Claims Administrator or Lead Counsel:

Lead Counsel: Shannon L. Hopkins, Esq., LEVI & KORSINSKY, LLP  
1111 Summer Street, Suite 403, Stamford, Connecticut 06905  
Tel: (203) 992-4523; fax: (212) 363-7171

Claims Administrator: *Meridian Bioscience Sec. Litigation*, c/o A.B. DATA, LTD.  
P.O. Box 173081, Milwaukee, WI 53217  
Tel: 800-331-8642  
Email: [info@meridiansecuritieslitigation.com](mailto:info@meridiansecuritieslitigation.com)

**WHAT THIS NOTICE CONTAINS**

<b>TABLE OF CONTENTS</b>	<b>PAGE</b>
<b>Basic Information</b>	
1. Why did I get this notice package? .....	3
2. What is this lawsuit about?.....	3
3. Why is this a class action?.....	3
4. Why is there a settlement? .....	3
<b>Who Is Part of the Settlement?</b>	
5. How do I know if I am part of the Settlement?.....	4
6. Are there exceptions to being included? .....	4
7. What if I am still not sure if I am included?.....	4
<b>What Are the Settlement Benefits?</b>	
8. What does the Settlement provide?.....	4
9. How will the Settlement be allocated among class members?.....	5
10. How much will my payment be?.....	11
<b>How Can You Receive a Payment?</b>	
11. How can I get a payment? .....	11
12. When would I get my payment? .....	11
13. What am I giving up to get a payment or stay in the Settlement Class?.....	11
<b>Excluding Yourself from the Settlement</b>	
14. How do I exclude myself from the proposed Settlement? .....	12
15. If I do not exclude myself, can I sue Meridian, Defendants or the other Released Persons later for the Released Claims? .....	12
16. If I exclude myself, can I get money from the proposed Settlement? .....	12
<b>The Lawyers Representing You</b>	
17. Do I have a lawyer in this case?.....	12
18. How will the lawyers be paid?.....	12
<b>Objecting to the Settlement</b>	
19. How do I tell the Court that I do not like the proposed Settlement? .....	13
20. What is the difference between objecting and excluding? .....	13
<b>The Court's Settlement Hearing</b>	
21. When and where will the Court decide whether to approve the proposed Settlement? .....	13
22. Do I have to come to the hearing?.....	13
23. May I speak at the hearing?.....	13

**If You Do Nothing**

24. What happens if I do nothing at all? ..... 14

**Getting More Information**

25. Are there more details about the proposed Settlement? ..... 14

**BASIC INFORMATION**

**1. Why did I get this notice package?**

You or someone in your family may have purchased or otherwise acquired Meridian common stock on a United States stock exchange during the Class Period. The Court directed that this Notice be sent to potential Settlement Class Members because they have a right to know about a proposed settlement of a class action lawsuit, and about all of their options, before the Court decides whether to approve the Settlement. If the Court approves the Settlement and any appeals are resolved, an administrator appointed by the Court will make the payments that the Settlement allows.

The Court in charge of the case is the United States District Court for the Southern District of Ohio, and the case is *Forman v. Meridian Bioscience, Inc., et al.*, Case No. 1:17-cv-00774-SJD (the “Action”).

**2. What is this lawsuit about?**

The Amended Complaint (the “Complaint”) filed on April 16, 2018, alleges that Defendants Meridian, John A. Kraeutler, and Melissa A. Lueke (“Defendants”) violated Sections 10(b) and 20(a) of the Exchange Act of 1934. Plaintiff contends that these Defendants engaged in a scheme to conceal the fact that every lead testing product Meridian offered underestimated blood lead levels, thereby endangering at-risk individuals who relied on the results of these tests. The Complaint alleges that, when the scheme became public through various partial announcements, Meridian’s share price fell and shareholders were damaged. The Action seeks money damages against Defendants. Defendants deny all of Plaintiff’s allegations, deny that they made any false or misleading statements or otherwise did anything wrong, and deny that anything they did caused damages to Plaintiff or the Settlement Class.

**3. Why is this a class action?**

In a class action, one or more people called “Class Representative” (in this case, Barbara Forman), sue on behalf of people who have similar claims. All persons with similar claims are called a “Class” or “Class Members.” Bringing a case, such as this one, as a class action allows the collective adjudication of many similar claims that might be economically too small to bring in individual actions. One judge resolves the issues for all class members, except for those who exclude themselves from the class. United States District Judge Susan J. Dlott of the Southern District of Ohio is overseeing the Action.

**4. Why is there a settlement?**

The Court did not decide in favor of Plaintiff or Defendants. Instead, the lawyers for both sides, with the assistance of a neutral third-party mediator, have negotiated a Settlement that they believe is in the best interests of their respective clients. The Settlement allows both sides to avoid the risks and cost of lengthy and uncertain litigation, trial, and appeals, and permits Settlement Class Members to be compensated more quickly.

In a decision dated February 13, 2019, the Court granted Defendants’ motion to dismiss Plaintiff’s Amended Complaint, dismissing the Action at that point. Following a motion by Plaintiff for reconsideration of the dismissal order, the Court found Plaintiff’s claims actionable as to a single misstatement contained in Meridian’s November 29, 2016 Annual Report filed on Form 10-K with the Securities and Exchange Commission.

If she continues to pursue litigation, Plaintiff faces the risk of failing to show, among other things, “loss causation” and “damages” – a requirement under the federal securities laws to prove that the alleged harm became publicly known to investors and caused a decline in stock price. To do so, Plaintiff would need proof that new information corrected old information and caused a drop in the value of Meridian’s stock. The Amended Complaint alleges that loss causation exists primarily as to three events. First, the stock price dropped \$3.65 in January 2017 when the Company announced it was both reducing its regular cash dividend and revising its fiscal 2017 guidance downward. Second, the stock price dropped \$1.30 in May 2017 when the FDA issued a public safety announcement, warning against the use of LeadCare products because of their issues with underestimating lead levels in vein-drawn blood. Third, the FDA issued a formal warning letter disclosing to the market the full extent of the Company’s non-compliance with FDA regulations. This caused the stock price to drop \$0.60. Consequently, Plaintiff believes she is entitled to damages associated with each of

those drops. However, there is a significant risk that the Court, which significantly narrowed the scope of the case in its motion to dismiss order—will find that the alleged misconduct did not cause the drops. Accordingly, and as explained above, Class Representative and her attorneys think the Settlement is best for all Settlement Class Members.

### **WHO IS PART OF THE SETTLEMENT?**

#### **5. How do I know if I am part of the Settlement?**

The Court directed that, for the purposes of the proposed Settlement, everyone who fits this description is a Settlement Class Member: all persons or entities who purchased or otherwise acquired securities of Meridian Bioscience, Inc. (“Meridian” or the “Company”) between March 24, 2016 and October 23, 2017 and who were damaged thereby.

#### **6. Are there exceptions to being included?**

Yes. Excluded from the Settlement Class are Defendants; members of the Defendants’ immediate families; officers, directors, and subsidiaries of Meridian; any firm, entity, or corporation wholly owned by any Defendant and/or any member(s) of a Defendant’s immediate family; any trust of which a Defendant is the settlor or which is for his or her benefit and/or that of any member of his or her immediate family (as defined by SEC regulations); and the legal representatives, heirs, or successors-in-interest of the Settling Defendants. Also excluded from the Settlement Class are those Persons who timely and validly request exclusion from the Settlement Class in accordance with the instructions provided in this Notice.

If one of the mutual funds in which you are invested purchased or otherwise acquired Meridian common stock during the Class Period, that does not make you a Settlement Class Member. You are a Settlement Class Member only if you directly purchased or otherwise acquired Meridian common stock during the Class Period. Contact your broker to see if you fall within the definition of a Settlement Class Member.

If you **sold** but did not purchase Meridian common stock during the Class Period, you are not a Settlement Class Member. You are a Settlement Class Member only if you **purchased or otherwise acquired** Meridian securities during the Class Period.

#### **7. What if I am still not sure if I am included?**

If you are still not sure whether you are included, you can ask for free help. You can contact the Claims Administrator by writing to the address provided on p. 2 above for more information.

### **WHAT ARE THE SETTLEMENT BENEFITS?**

#### **8. What does the Settlement provide?**

Meridian has agreed to pay or cause to be paid \$2.1 million in cash (the “Settlement Fund”) on behalf of all Defendants. The Settlement Fund, plus interest earned from the date it is established, less costs, fees, and expenses (the “Net Settlement Fund”), will be divided among all eligible Settlement Class Members who send in valid and timely Proof of Claim and Release forms (“Authorized Claimants”). Costs, fees, and expenses include Court-approved attorneys’ fees and expenses; certain Notice and Administration Costs, including the costs of printing and mailing this Notice, the cost of publishing notice, and the costs of claims administration; and Taxes on the Settlement Fund.

In return, the Parties have agreed to dismiss the Action and Plaintiff and all Settlement Class Members who do not exclude themselves from the Settlement Class agree to release, relinquish and discharge all Released Claims against the Defendants and their respective Related Persons (collectively, the “Released Persons”), whether or not these Settlement Class Members execute and deliver Proof of Claim and Release forms.

## PLAN OF ALLOCATION

### 9. How will the Settlement be allocated among Settlement Class Members?

#### **Calculation of Recognized Loss for the Purchase of Meridian Bioscience, Inc. (Ticker: VIVO) Common Shares in the Open Market on or between March 24, 2016 and October 23, 2017**

Common shares of Meridian Bioscience, Inc. (“Meridian”) purchased on or between March 24, 2016 and October 23, 2017 and held until the close of trading on January 24, 2017, May 16, 2017, and/or October 23, 2017 shall be entitled to damages (“1934 Act Class shares”) for the purposes of the 1934 Exchange Act (“1934 Act Class”). The total number of 1934 Act Class shares is estimated to be 18.4 million, although many shares will be entitled to no damages or substantially reduced damages under the plan of allocation. The settlement amount is \$2.1 million or approximately \$0.114 per damaged shares.

**For each eligible share purchased on or after March 24, 2016 and before November 28, 2016, the Recognized Loss for each such share shall be *the lesser of*:**

- (i) the recognized loss based on the date of sale as set forth in Table 1;

**Table 1: Recognized Losses for 1934 Act Class Shares Based on Date of Sale**

<b>Begin Sale Date</b>	<b>End Sale Date</b>	<b>Recognized Loss</b>
3/24/2016	01/24/2017	\$ 0.00
1/25/2017	05/16/2017	\$ 0.09
05/17/2017	10/20/2017	\$ 0.19
10/23/2017	Current	\$ 0.22

- (ii) the purchase price (excluding fees and commissions) minus the sale price (excluding fees and commissions) if sold prior to January 19, 2018; and,
- (iii) the purchase price (excluding fees and commissions) minus the 90-LookBack Average price as set forth in Table 3 if sold after October 20, 2017, and before January 19, 2018, or minus \$14.67 per share if not sold prior to January 19, 2018.

**For each eligible share purchased on or after November 28, 2016, and on or before October 20, 2017, the Recognized Loss for each such share shall be *the lesser of*:**

- (i) the recognized loss based on the date of sale **minus** the recognized loss as of the date of purchase as set forth in Table 2;

**Table 2: Recognized Losses for 1934 Act Class Shares Based on Date of Sale and Date of Purchase**

<b>Begin Date</b>	<b>End Date</b>	<b>Recognized Loss</b>
11/28/2016	01/24/2017	\$ 0.00
1/25/2017	05/16/2017	\$ 0.83
05/17/2017	10/20/2017	\$ 1.90
10/23/2017	Current	\$ 2.19

- (ii) the purchase price (excluding fees and commissions) minus the sale price (excluding fees and commissions) if sold prior to January 19, 2018; and,

- (iii) the purchase price (excluding fees and commissions) minus the LookBack Average price as set forth in Table 3 if sold after October 23, 2017, and before January 19, 2018, or minus \$14.67 per share if not sold prior to January 19, 2018.

**For each eligible share purchased on October 23, 2017, the Recognized Loss for each such share shall be *the lesser of*:**

- (i) the 50% of the difference between the purchase price and \$15.20 (if the purchase price was greater than \$15.20; zero otherwise);
- (ii) the purchase price (excluding fees and commissions) minus the sale price (excluding fees and commissions) if sold prior to January 19, 2018; and,
- (iii) the purchase price (excluding fees and commissions) minus the LookBack Average price as set forth in Table 3 if sold before January 19, 2018, or minus \$14.67 per share if not sold prior to January 19, 2018.

**Table 3: 90-LookBack Price Based on Date of Sale**

Sale Date	Closing Price	LookBack Average Price
10/23/2017	\$15.20	\$15.20
10/24/2017	\$14.50	\$14.85
10/25/2017	\$14.90	\$14.87
10/26/2017	\$14.70	\$14.83
10/27/2017	\$15.30	\$14.92
10/30/2017	\$14.70	\$14.88
10/31/2017	\$14.95	\$14.89
11/1/2017	\$14.70	\$14.87
11/2/2017	\$14.40	\$14.82
11/3/2017	\$14.65	\$14.80
11/6/2017	\$14.95	\$14.81
11/7/2017	\$14.65	\$14.80
11/8/2017	\$14.65	\$14.79
11/9/2017	\$14.80	\$14.79
11/10/2017	\$14.55	\$14.77
11/13/2017	\$14.60	\$14.76
11/14/2017	\$14.90	\$14.77
11/15/2017	\$14.65	\$14.76
11/16/2017	\$14.95	\$14.77
11/17/2017	\$14.95	\$14.78
11/20/2017	\$14.85	\$14.79
11/21/2017	\$14.90	\$14.79
11/22/2017	\$14.85	\$14.79
11/24/2017	\$14.95	\$14.80
11/27/2017	\$14.60	\$14.79
11/28/2017	\$14.55	\$14.78
11/29/2017	\$14.75	\$14.78
11/30/2017	\$15.05	\$14.79
12/1/2017	\$14.85	\$14.79
12/4/2017	\$15.15	\$14.81
12/5/2017	\$14.80	\$14.80

Sale Date	Closing Price	LookBack Average Price
12/6/2017	\$14.60	\$14.80
12/7/2017	\$14.05	\$14.78
12/8/2017	\$14.10	\$14.76
12/11/2017	\$14.15	\$14.74
12/12/2017	\$14.10	\$14.72
12/13/2017	\$14.20	\$14.71
12/14/2017	\$13.55	\$14.68
12/15/2017	\$14.25	\$14.67
12/18/2017	\$14.10	\$14.65
12/19/2017	\$14.25	\$14.64
12/20/2017	\$14.60	\$14.64
12/21/2017	\$14.60	\$14.64
12/22/2017	\$14.25	\$14.63
12/26/2017	\$14.25	\$14.62
12/27/2017	\$14.20	\$14.61
12/28/2017	\$14.15	\$14.60
12/29/2017	\$14.00	\$14.59
1/2/2018	\$14.40	\$14.59
1/3/2018	\$14.65	\$14.59
1/4/2018	\$14.65	\$14.59
1/5/2018	\$15.10	\$14.60
1/8/2018	\$14.80	\$14.60
1/9/2018	\$14.70	\$14.60
1/10/2018	\$15.10	\$14.61
1/11/2018	\$15.45	\$14.63
1/12/2018	\$15.30	\$14.64
1/16/2018	\$15.30	\$14.65
1/17/2018	\$15.25	\$14.66
1/18/2018	\$14.95	\$14.67
1/19/2018	\$15.15	\$14.67

**Calculation of Recognized Loss for the Purchase of Meridian Bioscience, Inc. (Ticker: VIVO) Call Options in the Open Market on or between March 24, 2016 and October 23, 2017**

Call options of Meridian Bioscience, Inc. (“Meridian”) purchased on or between March 24, 2016 and October 23, 2017 and held until the close of trading on January 24, 2017, the close of trading on May 16, 2017, or until the beginning of trading on October 24, 2017 shall be entitled to damages (“1934 Act Class shares”) for the purposes of the 1934 Exchange Act (“1934 Act Class”). The total number of 1934 Act options traded is not known but is believed to be relatively small in comparison with the damaged shares. To the extent a call option purchased in the open market has an exercise price after a given damage date but not on one of the exercise dates provided, the damages will be the averaged amount between the two closest expiration dates in the table or the last expiration date listed if the expiration date is beyond January 18, 2019. An option position created before one corrective disclosure date and sold after a second or third disclosure date will be entitled to damages on each corrective date.

**Call Option Damages at January 25, 2017**

For call options purchased prior to January 24, 2017, and held until at least January 25, 2017, the following damages in Table 4 will be allocated on a per share basis for each given exercise (strike) price and each given expiration date. For call options purchased on or after March 24, 2016 and before November 28, 2016, the amount of damages will be reduced to 10% of the per share amounts in Table 4.

**Table 4:  
Per Share Damages for Call Options Purchased Prior to January 24, 2017 and held Until January 25, 2017**

	2/17/2017	3/17/2017	4/21/2017	5/19/2017	6/16/2017	7/21/2017	10/20/2017	11/17/2017	12/15/2017	1/29/2018	2/16/2018	3/16/2018	4/20/2018	7/20/2018	10/19/2018	1/18/2019
<b>Exercise Prices</b>																
\$ 2.50	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83
\$ 5.00	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83
\$ 7.50	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.82	\$ 0.82
\$ 10.00	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.82	\$ 0.81	\$ 0.81	\$ 0.81	\$ 0.80	\$ 0.80	\$ 0.80	\$ 0.78	\$ 0.77	\$ 0.76
\$ 12.50	\$ 0.83	\$ 0.83	\$ 0.82	\$ 0.80	\$ 0.79	\$ 0.77	\$ 0.73	\$ 0.72	\$ 0.71	\$ 0.70	\$ 0.70	\$ 0.69	\$ 0.69	\$ 0.67	\$ 0.66	\$ 0.65
\$ 15.00	\$ 0.70	\$ 0.64	\$ 0.60	\$ 0.56	\$ 0.55	\$ 0.55	\$ 0.53	\$ 0.52	\$ 0.52	\$ 0.52	\$ 0.51	\$ 0.51	\$ 0.51	\$ 0.51	\$ 0.50	\$ 0.50
\$ 17.50	\$ 0.05	\$ 0.13	\$ 0.19	\$ 0.21	\$ 0.24	\$ 0.27	\$ 0.30	\$ 0.30	\$ 0.31	\$ 0.32	\$ 0.31	\$ 0.32	\$ 0.33	\$ 0.34	\$ 0.35	\$ 0.36
\$ 20.00	\$ 0.00	\$ 0.00	\$ 0.02	\$ 0.04	\$ 0.06	\$ 0.09	\$ 0.14	\$ 0.14	\$ 0.15	\$ 0.17	\$ 0.17	\$ 0.18	\$ 0.19	\$ 0.21	\$ 0.23	\$ 0.24
\$ 22.50	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.01	\$ 0.02	\$ 0.05	\$ 0.06	\$ 0.07	\$ 0.08	\$ 0.08	\$ 0.09	\$ 0.10	\$ 0.12	\$ 0.14	\$ 0.16
\$ 25.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.01	\$ 0.02	\$ 0.02	\$ 0.03	\$ 0.04	\$ 0.04	\$ 0.04	\$ 0.05	\$ 0.07	\$ 0.09	\$ 0.10
\$ 30.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.02	\$ 0.03	\$ 0.04

**Call Option Damages at May 17, 2017**

For call options purchased prior to May 17, 2017, and held until at least May 17, 2017, the following damages in Table 5 will be allocated on a per share basis for each given exercise (strike) price and each given expiration date. For call options purchased on or after March 24, 2016 and before November 28, 2016, the amount of damages will be reduced to 10% of the per share amounts in Table 5.

**Table 5  
Per Share Damages for Call Options Purchased Prior to May 17, 2017 and Held Until May 17, 2017**

	Expiration Dates													
	5/19/2017	6/16/2017	7/21/2017	10/20/2017	11/17/2017	12/15/2017	1/29/2018	2/16/2018	3/16/2018	4/20/2018	7/20/2018	10/19/2018	1/18/2019	
<b>Exercise Prices</b>														
\$ 2.50	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	
\$ 5.00	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.06	
\$ 7.50	1.07	1.07	1.07	1.07	1.06	1.06	1.06	1.05	1.05	1.05	1.03	1.02	1.01	
\$ 10.00	1.07	1.06	1.04	1.00	0.98	0.97	0.96	0.95	0.95	0.94	0.92	0.90	0.89	
\$ 12.50	0.90	0.88	0.84	0.79	0.77	0.76	0.76	0.75	0.75	0.75	0.74	0.73	0.72	
\$ 15.00	0.41	0.43	0.47	0.50	0.50	0.51	0.52	0.51	0.52	0.53	0.54	0.55	0.55	
\$ 17.50	0.09	0.12	0.19	0.27	0.28	0.30	0.32	0.32	0.33	0.34	0.37	0.39	0.41	
\$ 20.00	0.01	0.02	0.06	0.12	0.14	0.16	0.18	0.18	0.19	0.21	0.24	0.27	0.29	
\$ 22.50	0.00	0.00	0.01	0.05	0.06	0.08	0.10	0.10	0.11	0.12	0.15	0.18	0.20	
\$ 25.00	0.00	0.00	0.00	0.02	0.03	0.04	0.05	0.05	0.06	0.07	0.10	0.12	0.14	
\$ 30.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.02	0.02	0.04	0.05	0.07	

## Call Option Damages at October 23, 2017

For call options purchased prior to October 23, 2017, and held until at least October 23, 2017, the following damages in Table 6 will be allocated on a per share basis for each given exercise (strike) price and each given expiration date. For call options purchased on or after March 24, 2016 and before November 28, 2016, the amount of damages will be reduced to 10% of the per share amounts in Table 6.

**Table 6**  
**Per Share Damages for Call Options Purchased Prior to October 23, 2017, and Held Until October 23, 2017**

		Expiration Dates								
		11/17/2017	12/15/2017	1/29/2018	2/16/2018	3/16/2018	4/20/2018	7/20/2018	10/19/2018	1/18/2019
Exercise Prices										
\$	2.50	0.29	0.29	0.29	0.29	0.29	0.29	0.29	0.29	0.29
\$	5.00	0.29	0.29	0.29	0.29	0.29	0.29	0.29	0.29	0.29
\$	7.50	0.29	0.29	0.29	0.29	0.29	0.29	0.29	0.28	0.28
\$	10.00	0.28	0.28	0.28	0.27	0.27	0.27	0.27	0.26	0.26
\$	12.50	0.24	0.24	0.24	0.24	0.23	0.23	0.23	0.22	0.22
\$	15.00	0.18	0.18	0.18	0.18	0.18	0.18	0.18	0.18	0.18
\$	17.50	0.12	0.12	0.12	0.12	0.12	0.13	0.13	0.14	0.14
\$	20.00	0.07	0.07	0.08	0.08	0.08	0.08	0.09	0.10	0.11
\$	22.50	0.04	0.04	0.04	0.04	0.05	0.05	0.06	0.07	0.08
\$	25.00	0.02	0.02	0.02	0.02	0.03	0.03	0.04	0.05	0.06
\$	30.00	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.02	0.03

## Calculation of Recognized Loss for the Sale/Writing of Meridian Bioscience, Inc. (Ticker: VIVO) Put Options in the Open Market on or between March 24, 2016 and October 23, 2017

Put options of Meridian Bioscience, Inc. (“Meridian”) written (sold) on or between March 24, 2016 and October 23, 2017 and held until the close of trading on January 24, 2017, the close of trading on May 16, 2017, or until the beginning of trading on October 23, 2017 shall be entitled to damages (“1934 Act Class shares”) for the purposes of the 1934 Exchange Act (“1934 Act Class”). The total number of 1934 Act options traded is not known but is believed to be relatively small in comparison with the damaged shares. To the extent a put option purchased in the open market has an exercise price after a given damage date but not on one of the exercise dates provided, the damages will be the averaged amount between the two closest expiration dates in the table or the last expiration date listed if the expiration date is beyond January 18, 2019.

## Put Option Damages at January 25, 2017

For put options written (sold) prior to January 24, 2017, and held until at least January 25, 2017, the following damages in Table 7 will be allocated on a per share basis for each given exercise (strike) price and each given expiration date. For put options written on or after March 24, 2016 and before November 28, 2016, the amount of damages will be reduced to 10% of the per share amounts in Table 7.

**Table 7**  
**Per Share Damages for Put Options Written Prior to January 25, 2017 and Held Until January 25, 2017**

Exercise Prices	Expiration Dates															
	2/17/2017	3/17/2017	4/21/2017	5/19/2017	6/16/2017	7/21/2017	10/20/2017	11/17/2017	12/15/2017	1/29/2018	2/16/2018	3/16/2018	4/20/2018	7/20/2018	10/19/2018	1/18/2019
\$ 2.50	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00
\$ 5.00	\$ -	\$ -	\$ -	\$ -	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00
\$ 7.50	\$ -	\$ -	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.01	\$ 0.01
\$ 10.00	\$ -	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.01	\$ 0.02	\$ 0.02	\$ 0.02	\$ 0.03	\$ 0.03	\$ 0.03	\$ 0.05	\$ 0.06
\$ 12.50	\$ 0.00	\$ 0.00	\$ 0.01	\$ 0.03	\$ 0.04	\$ 0.06	\$ 0.10	\$ 0.11	\$ 0.12	\$ 0.13	\$ 0.13	\$ 0.14	\$ 0.14	\$ 0.16	\$ 0.17	\$ 0.18
\$ 15.00	\$ 0.13	\$ 0.19	\$ 0.23	\$ 0.27	\$ 0.28	\$ 0.28	\$ 0.30	\$ 0.31	\$ 0.31	\$ 0.31	\$ 0.32	\$ 0.32	\$ 0.32	\$ 0.32	\$ 0.33	\$ 0.33
\$ 17.50	\$ 0.78	\$ 0.70	\$ 0.64	\$ 0.62	\$ 0.59	\$ 0.56	\$ 0.53	\$ 0.53	\$ 0.52	\$ 0.51	\$ 0.52	\$ 0.51	\$ 0.50	\$ 0.49	\$ 0.48	\$ 0.47
\$ 20.00	\$ 0.83	\$ 0.83	\$ 0.81	\$ 0.79	\$ 0.77	\$ 0.74	\$ 0.69	\$ 0.69	\$ 0.68	\$ 0.66	\$ 0.66	\$ 0.65	\$ 0.64	\$ 0.62	\$ 0.60	\$ 0.59
\$ 22.50	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.82	\$ 0.81	\$ 0.78	\$ 0.77	\$ 0.76	\$ 0.75	\$ 0.75	\$ 0.74	\$ 0.73	\$ 0.71	\$ 0.69	\$ 0.67
\$ 25.00	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.82	\$ 0.81	\$ 0.81	\$ 0.80	\$ 0.79	\$ 0.79	\$ 0.79	\$ 0.78	\$ 0.76	\$ 0.74	\$ 0.73
\$ 30.00	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.83	\$ 0.82	\$ 0.82	\$ 0.82	\$ 0.82	\$ 0.81	\$ 0.80	\$ 0.79

**Put Option Damages at May 17, 2017**

For put options purchased written prior to May 17, 2017, and held until at least May 17, 2017, the following damages in Table 8 will be allocated on a per share basis for each given exercise (strike) price and each given expiration date. For put options written on or after March 24, 2016 and before November 28, 2016, the amount of damages will be reduced to 10% of the per share amounts in Table 8.

**Table 8**  
**Per Share Damages for Put Options Written Before May 17, 2017 and Held Until May 17, 2017**

Exercise Prices	Expiration Dates													
	5/19/2017	6/16/2017	7/21/2017	10/20/2017	11/17/2017	12/15/2017	1/29/2018	2/16/2018	3/16/2018	4/20/2018	7/20/2018	10/19/2018	1/18/2019	
\$ 2.50	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
\$ 5.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	
\$ 7.50	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.02	0.02	0.02	0.04	0.05	0.06	
\$ 10.00	0.00	0.01	0.03	0.07	0.09	0.10	0.11	0.12	0.12	0.13	0.15	0.17	0.18	
\$ 12.50	0.17	0.19	0.23	0.28	0.30	0.31	0.31	0.32	0.32	0.32	0.33	0.34	0.35	
\$ 15.00	0.66	0.64	0.60	0.57	0.57	0.56	0.55	0.56	0.55	0.54	0.53	0.52	0.52	
\$ 17.50	0.98	0.95	0.88	0.80	0.79	0.77	0.75	0.75	0.74	0.73	0.70	0.68	0.66	
\$ 20.00	1.06	1.05	1.01	0.95	0.93	0.91	0.89	0.89	0.88	0.86	0.83	0.80	0.78	
\$ 22.50	1.07	1.07	1.06	1.02	1.01	0.99	0.97	0.97	0.96	0.95	0.92	0.89	0.87	
\$ 25.00	1.07	1.07	1.07	1.05	1.04	1.03	1.02	1.02	1.01	1.00	0.97	0.95	0.93	
\$ 30.00	1.07	1.07	1.07	1.07	1.07	1.06	1.06	1.06	1.05	1.05	1.03	1.02	1.00	

**Put Option Damages at October 23, 2017**

For put options purchased written prior to October 23, 2017, and held until at least October 23, 2017, the following damages in Table 9 will be allocated on a per share basis for each given exercise (strike) price and each given expiration date. For put options written on or after March 24, 2016 and before November 28, 2016, the amount of damages will be reduced to 10% of the per share amounts in Table 9.

**Table 9**  
**Per Share Damages for Put Options Written Prior to October 23, 2017 and Held Until October 23, 2017**

		Expiration Dates								
		11/17/2017	12/15/2017	1/29/2018	2/16/2018	3/16/2018	4/20/2018	7/20/2018	10/19/2018	1/18/2019
<b>Exercise Prices</b>										
\$	2.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
\$	5.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
\$	7.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01
\$	10.00	0.01	0.01	0.01	0.02	0.02	0.02	0.02	0.03	0.03
\$	12.50	0.05	0.05	0.05	0.05	0.06	0.06	0.06	0.07	0.07
\$	15.00	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.11
\$	17.50	0.17	0.17	0.17	0.17	0.17	0.16	0.16	0.15	0.15
\$	20.00	0.22	0.22	0.21	0.21	0.21	0.21	0.20	0.19	0.18
\$	22.50	0.25	0.25	0.25	0.25	0.24	0.24	0.23	0.22	0.21
\$	25.00	0.27	0.27	0.27	0.27	0.26	0.26	0.25	0.24	0.23
\$	30.00	0.28	0.28	0.28	0.28	0.28	0.28	0.27	0.27	0.26

**Allocations of Net Proceeds Received in Settlement Based on Recognized Claims**

There shall be no Recognized Loss attributed to any Meridian security purchased on a foreign exchange or over-the-counter (*i.e.* non-market options).

For all purposes the transaction date and not the settlement date shall be used as the date for determining Eligible Loss per share, eligibility to file a claim, and the calculation of Recognized Losses. All purchases and sales of Trust Units shall be accounted for and matched using the first-in-first-out (FIFO) method of accounting and gains on short sales of Meridian shares (if any) on or between March 24, 2016, and October 20, 2017, will be used to offset losses. All effective “recognized gains” from short positions, including written (sold) call options and purchased put options will be considered as offsetting any losses on a per share basis based on Table 1 through 9.

The receipt or grant by gift, inheritance or operation of law of Meridian securities during the Settlement Class Period shall not be deemed a purchase, acquisition or sale of Meridian securities for the calculation of an Authorized Claimant’s Recognized Loss Amount, nor shall the receipt or grant be deemed an assignment of any claim relating to the purchase/acquisition of any Meridian securities unless (i) the donor or decedent purchased or otherwise acquired such Meridian securities during the Settlement Class Period; (ii) no Claim Form was submitted by or on behalf of the donor, on behalf of the decedent, or by anyone else with respect to such Meridian securities; and (iii) it is specifically so provided in the instrument of gift or assignment.

A Claimant’s “Recognized Claim” under the Plan of Allocation shall be the sum of his, her or its Recognized Loss Amounts minus the sum of Recognized Gain Amounts.

The Net Settlement Fund will be distributed to Authorized Claimants on a pro rata basis based on the relative size of their Recognized Claims. Specifically, a “Distribution Amount” will be calculated for each Authorized Claimant, which shall be the Authorized Claimant’s Recognized Claim divided by the total Recognized Claims of all Authorized Claimants, multiplied by the total amount in the Net Settlement Fund. Given the costs of distribution, the Net Settlement Fund will be allocated among all Authorized Claimants whose Distribution Amount (defined in ¶ 10 below) is \$10.00 or greater. Consequently, no cash payment will be made on a claim where the potential distribution amount is less than \$10.00.

If the Net Settlement Fund exceeds the sum total amount of the Recognized Losses of all Authorized Claimants entitled to receive payment out of the Net Settlement Fund, the excess amount in the Net Settlement Fund shall be distributed pro rata to all Authorized Claimants entitled to receive payment.

Settlement Class Members who do not submit a valid and timely Proof of Claim and Release form will not share in the Settlement proceeds, but will nevertheless be bound by the Settlement, the Judgment of the Court dismissing this Action, and the releases provided therein.

If you did not incur a Recognized Loss as defined in the Plan of Allocation, you will not receive a cash distribution from the Net Settlement Fund, but you will be bound by all determinations and judgments of the Court in connection with the Settlement, including being barred from asserting any of the Released Claims against the Released Parties.

10. How much will my payment be?

If you are entitled to a payment, your share of the Net Settlement Fund will depend on the number of Authorized Claimants. Payments will be calculated on a *pro rata* basis, meaning that the Net Settlement Fund will be divided among the Authorized Claimants and distributed accordingly (the “Distribution Amount”) after the deadline for submission of Proof of Claim and Release forms has passed.

To the extent that any amount of the Net Settlement Fund remains after the Claims Administrator has caused distributions to be made to all Authorized Claimants, whether by reason of uncashed distributions or otherwise, then, after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants cash their distributions, any balance remaining in the Settlement Fund six (6) months after the initial distribution of such funds shall be redistributed to Authorized Claimants who have cashed their initial distributions, after payment of any unpaid costs or fees incurred in administering the Settlement Fund, if Lead Counsel, in consultation with the Claims Administrator, determines that additional redistributions, after deduction of any additional fees and expenses that would be incurred with respect to such redistribution, would be cost-effective. At such time as it is determined that the redistribution of funds remaining in the Settlement Fund is not cost-effective, the remaining balance in the Settlement Fund shall be contributed to non-sectarian, not-for-profit 501(c)(3) organization(s), to be recommended by Lead Counsel and approved by the Court.

11. How can I get a payment?

To qualify for a payment, you must be an eligible Settlement Class Member and send in a valid and timely Proof of Claim and Release form. You may download a Proof of Claim and Release form from the settlement website, [www.meridiansecuritieslitigation.com](http://www.meridiansecuritieslitigation.com). Read the instructions carefully, fill out the Proof of Claim and Release form, include all the documents the form asks for, sign it, and mail it postmarked no later than February 4, 2020 to the Claims Administrator (address provided on page 2). Any Settlement Class Member who fails to submit a Proof of Claim and Release form by such date shall be forever barred from receiving any distribution from the Net Settlement Fund (unless by order of the Court the deadline is extended or such Settlement Class Member’s Proof of Claim and Release form is accepted), but otherwise shall be bound by all of the terms of the Stipulation and the Judgment, including the releases therein, and will be permanently barred and enjoined from asserting any of the Released Claims against any of the Released Persons.

12. When would I get my payment?

The Court will hold a hearing on March 16, 2020 at 2:00 p.m., to decide whether to approve the Settlement. If the Settlement is approved, the Claims Administrator will complete the administration process and determine how much each Authorized Claimant is entitled to receive. Lead Counsel will then seek permission from the Court to distribute the Net Settlement Fund on a *pro rata* basis to Authorized Claimants. This is necessarily a long process.

13. What am I giving up to get a payment or stay in the Settlement Class?

Unless you exclude yourself, you will remain a Settlement Class Member, and that means that, upon the “Effective Date,” you will release all “Released Claims” against the “Released Persons.”

## EXCLUDING YOURSELF FROM THE SETTLEMENT

If you do not want a payment from this Settlement, but you want to keep any right you may have to sue or continue to sue Defendants on your own about the Released Claims, then you must take steps to exclude yourself—or as it is sometimes referred to, you must “opt out” of the Settlement Class.

### 14. How do I exclude myself from the proposed Settlement?

To exclude yourself from the Settlement Class, you must send a letter by first class mail stating that you “request exclusion from the Settlement Class in *Forman v. Meridian Bioscience, Inc., et al.*, Case No. 1:17-cv-00774-SJD (S.D. Ohio).” Your exclusion letter must legibly state the date(s), price(s) and number(s) of shares/contracts of all your purchases, acquisitions and sales of Meridian securities during the Class Period, and append supporting documentation (*i.e.* brokerage account statements). You must also include your name, mailing address, daytime telephone number, email address and your signature. Your exclusion letter must be postmarked **no later than February 17, 2020** and mailed by first class mail to the Claims Administrator, at:

Meridian Biosciences Sec. Litigation  
ATTN: EXCLUSIONS  
c/o A.B. Data, Ltd. – Class Action Administration  
P.O. Box 173001  
Milwaukee, WI 53217

**You cannot exclude yourself by telephone, by fax or by e-mail.** If you ask to be excluded, you will not get any payment or other benefit in the Settlement, and you cannot object to the Settlement. You will not be legally bound by the Settlement or Judgment or the releases therein, and you may be able to sue Meridian and the other Released Persons about the Released Claims in the future.

### 15. If I do not exclude myself, can I sue Meridian, Defendants or the other Released Persons later for the Released Claims?

No. Unless you exclude yourself, you give up any rights to sue Defendants and the other Released Persons, or to enforce any existing judgments against any of the Released Persons, for any and all Released Claims. If you have a pending lawsuit against Defendants or the other Released Persons, speak to your lawyer in that case immediately to determine if you have to exclude yourself from *this* Settlement Class to continue your own lawsuit. Remember, the exclusion deadline is **February 17, 2020**.

### 16. If I exclude myself, can I get money from the proposed Settlement?

No. If you exclude yourself, do not send in a Proof of Claim and Release form to ask for any money. But, you may exercise any right you may have to sue, continue to sue, or be part of a different lawsuit against Defendants and the other Released Persons.

## THE LAWYERS REPRESENTING YOU

### 17. Do I have a lawyer in this case?

The Court appointed the law firm Levi & Korsinsky, LLP to represent all Settlement Class Members. These lawyers are called “Lead Counsel.” You will **not** be separately charged for these lawyers. If you want to be represented by your own lawyer, you may hire one at your own expense.

### 18. How will the lawyers be paid?

Lead Counsel will ask the Court to award attorneys’ fees from the Settlement Fund in an amount not to exceed thirty percent (30%) of the Settlement Fund and for reimbursement of their expenses in an amount not to exceed \$70,000, plus interest on such fees and expenses at the same rate as earned by the Settlement Fund.

The attorneys’ fees and expenses requested will be the only payment to Lead Counsel for their efforts in achieving the Settlement and for their risk in undertaking this representation on a wholly contingent basis. To date, Lead Counsel has not been paid for their services in conducting this Action on behalf of Plaintiff and the Class nor for their substantial out-of-pocket expenses. The fees and expenses requested will compensate Lead Counsel for their work in obtaining the Settlement Fund for the Settlement Class. The Court may, however, award less than this amount. In that case, the difference will remain in the Settlement Fund. Lead Counsel will also seek payment of an award not to exceed \$10,000 to the Class Representative as compensation for her time and effort in representing the Class.

## OBJECTING TO THE SETTLEMENT

### 19. How do I tell the Court that I do not like the proposed Settlement?

If you are a Settlement Class Member, you can object to the Settlement or any of its terms, the proposed Plan of Allocation, the application by Lead Counsel for an award of fees and reimbursement of expenses, or the application for an award to Plaintiff. You may write to the Court setting out your objections. You may give reasons why you think the Court should not approve any or all of the settlement terms or arrangements and submit any documentation you believe is appropriate. The Court will only consider your views if you mail or file a proper objection within the deadline identified and according to the following procedures.

To object, you must send a signed letter or other court submission stating that you object to the proposed Settlement in *Forman v. Meridian Bioscience, Inc. et al.*, Case No. 1:17-cv-00774-SJD (S.D. Ohio). You must include your name, mailing address, daytime telephone number, email address and signature. In addition, your objection must be accompanied by documentation showing the date(s), price(s) and number(s) of shares of all purchases and sales of Meridian securities you made during the Class Period. Further, your objection should state the reasons why you object to the Settlement and be accompanied by any legal support or evidence that you wish the Court to consider. Your objection must be mailed and postmarked, or otherwise filed with the Court at the following address, **on or before February 17, 2020**:

Clerk of the Court  
United States District Court Southern District of Ohio  
Potter Stewart U.S. Courthouse  
Room 103  
100 East Fifth Street  
Cincinnati, Ohio 45202

### 20. What is the difference between objecting and excluding?

Objecting is simply telling the Court that you do not like something about the proposed Settlement. You can object only if you stay in the Settlement Class. Excluding yourself is telling the Court that you do not want to be part of the Settlement Class. If you exclude yourself, you cannot object because the case no longer affects you.

## THE COURT'S SETTLEMENT HEARING

### 21. When and where will the Court decide whether to approve the proposed Settlement?

The Court will hold a Final Approval Hearing at 2:00 p.m. on March 16, 2020, before the Honorable Susan J. Dlott in Courtroom 7, Room 117 of the United States District Court for the Southern District of Ohio, 100 East Fifth Street, Cincinnati, OH 45202. At this hearing, the Court will consider whether the Settlement is fair, reasonable and adequate. At the Final Approval Hearing, the Court also will consider the proposed Plan of Allocation for the proceeds of the Settlement, the application of Lead Counsel for attorneys' fees, and reimbursement of expenses, and the application for an award to Plaintiff. The Court will take into consideration any written objections and will listen to Settlement Class Members who have asked to speak at the hearing. The Court may change the date and time of the Final Approval Hearing without notice. Please check with Lead Counsel before coming to be sure that the date and/or time has not changed.

### 22. Do I have to come to the hearing?

No. Lead Counsel will answer questions the Court may have, but you are welcome to come at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you filed your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but attendance is not mandatory. Settlement Class Members do not need to appear at the Final Approval Hearing or take any other action to indicate their approval.

### 23. May I speak at the hearing?

If you object to the Settlement, you may ask the Court for permission to speak at the Final Approval Hearing. To do so, you must indicate in your written objection (or in a separate writing mailed or filed in the same manner) that it is your "Intention to Appear in *Forman v. Meridian Bioscience, Inc., et al.*, Case No. 1:17-cv-00774-SJD (S.D. Ohio)." Settlement Class Members who object to the Settlement, the Plan of Allocation, Lead Counsel's application for an award of attorneys' fees and reimbursement of expenses, or an award to Plaintiff and who desire to present evidence at the Final Approval Hearing must include in their written objections the identity of any witnesses they propose to call to testify and

any exhibits they intend to offer into evidence at the Final Approval Hearing. You cannot speak at the hearing if you exclude yourself from the Settlement Class or if you fail to provide written notice of your intention to speak at the Final Approval Hearing by the deadline identified.

**IF YOU DO NOTHING**

24. What happens if I do nothing at all?

If you do nothing, you will get no money from this Settlement and, unless you exclude yourself, you will not be able to start a lawsuit, continue with a lawsuit or be part of any other lawsuit against Defendants or the Released Persons about the claims being released in the Settlement. All Settlement Class Members who do not submit valid and timely Proof of Claim and Release forms shall be forever barred from receiving any payments from the Settlement, but will in all other respects be subject to and bound by the provisions of the Stipulation and any Judgment entered, including the releases set forth therein.

**GETTING MORE INFORMATION**

25. Are there more details about the proposed Settlement?

This Notice summarizes the proposed Settlement. More details are in the Stipulation. You may obtain a copy of the Stipulation by contacting the Claims Administrator by email or mail at the address and website provided on page 2, above, to obtain information and forms. The pleadings and other court filings in the Action are available for inspection during regular business hours at the Office of the Clerk of the United States District Court for the Southern District of Ohio, 100 East Fifth Street, Cincinnati, OH 45202.

**DO NOT TELEPHONE THE COURT REGARDING THIS NOTICE.**

**SPECIAL NOTICE TO NOMINEES**

If you hold Meridian securities pursuant to a transaction that took place within the United States within the Class Period, as nominee for a beneficial owner, then you must: within ten (10) calendar days of receipt of the Postcard Notice or this Notice, provide to the Claims Administrator the name, the last known mailing address, and email address of each Person for whom they purchased Meridian securities for during the Settlement Class Period.

Upon timely completion of this research and provision of information to the Claims Administrator, you may obtain reimbursement for or advancement of reasonable administrative costs (not to exceed \$0.15 per Settlement Class Member identified) actually incurred.

The Claims Administrator is not permitted to provide Nominee Purchasers with bulk copies of the Postcard Notice or this Notice for dissemination to Settlement Class Members, and Nominee Purchasers are not eligible for reimbursement of their print, postage and other expenses incurred due to their own dissemination of the Postcard Notice or this Notice to potential Settlement Class Members.

Dated: November 6, 2019

BY ORDER OF THE COURT  
UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF OHIO